OBJECTIVE: The purpose of this study is to examine autoantibody profile of systemic lupus erythematosus (SLE) patients with lupus nephritis (LN) and to establish the correlation between the antibody reactivity and disease activity of LN. METHODS: Autoantibodies and serological parameters were measured and analyzed in 589 SLE patients. The associations of the co-positivity of anti-dsDNA, -nucleosome and -histone antibodies (3-pos) with clinical, serological and outcome parameters were analyzed. RESULTS: At the study entry, the prevalence for anti-dsDNA (61.52 % vs. 34.11 %, P < 0.0001), anti-nucleosome (56.09 % vs. 37.21 %, P = 0.0002) and anti-histone (49.35 % vs. 33.33 %, P = 0.0013) antibodies in patients with LN were significantly higher than that in patients without LN. Patients with 3-pos had a higher proportion of proliferative renal lesions (class III + IV). The incidence of a poor renal outcome (7.14 % vs. 2.52 %, P = 0.0174) in LN patients with 3-pos was significantly higher than those without 3-pos. Moreover, the rate of remission (73.63 % vs. 82.37 %, P = 0.0245) was significantly reduced and recurrence increased (58.90 % vs. 23.44 %, P < 0.0001) in 3-pos patients as compared to that in non 3-pos within the LN group. CONCLUSION: Our data indicate a strong association between the 3-pos and renal disease activities, especially proliferative glomerulonephritis. The ability of 3-pos to predict renal flares may lead to major additional benefits in the follow-up of these patients.
OBJECTIVE: The purpose of this study is to examine autoantibody profile of systemic lupus erythematosus (SLE) patients with lupus nephritis (LN) and to establish the correlation between the antibody reactivity and disease activity of LN. METHODS: Autoantibodies and serological parameters were measured and analyzed in 589 SLEpatients. The associations of the co-positivity of anti-dsDNA, -nucleosome and -histone antibodies (3-pos) with clinical, serological and outcome parameters were analyzed. RESULTS: At the study entry, the prevalence for anti-dsDNA (61.52 % vs. 34.11 %, P < 0.0001), anti-nucleosome (56.09 % vs. 37.21 %, P = 0.0002) and anti-histone (49.35 % vs. 33.33 %, P = 0.0013) antibodies in patients with LN were significantly higher than that in patients without LN. Patients with 3-pos had a higher proportion of proliferative renal lesions (class III + IV). The incidence of a poor renal outcome (7.14 % vs. 2.52 %, P = 0.0174) in LN patients with 3-pos was significantly higher than those without 3-pos. Moreover, the rate of remission (73.63 % vs. 82.37 %, P = 0.0245) was significantly reduced and recurrence increased (58.90 % vs. 23.44 %, P < 0.0001) in 3-pos patients as compared to that in non 3-pos within the LN group. CONCLUSION: Our data indicate a strong association between the 3-pos and renal disease activities, especially proliferative glomerulonephritis. The ability of 3-pos to predict renal flares may lead to major additional benefits in the follow-up of these patients.
Authors: Mariann H Jørgensen; Ole Petter Rekvig; Rasmus S Jacobsen; Søren Jacobsen; Kristin A Fenton Journal: Immunol Lett Date: 2011-04-17 Impact factor: 3.685
Authors: S Fismen; A Hedberg; K A Fenton; S Jacobsen; E Krarup; A L Kamper; O P Rekvig; E S Mortensen Journal: Lupus Date: 2009-06 Impact factor: 2.911
Authors: Jürgen W Dieker; Justin H Fransen; Casandra C van Bavel; Jean-Paul Briand; Cor W Jacobs; Sylviane Muller; Jo H Berden; Johan van der Vlag Journal: Arthritis Rheum Date: 2007-06
Authors: Maurizio Bruschi; Renato Alberto Sinico; Gabriella Moroni; Federico Pratesi; Paola Migliorini; Maricla Galetti; Corrado Murtas; Angela Tincani; Michael Madaio; Antonella Radice; Franco Franceschini; Barbara Trezzi; Laura Bianchi; Agata Giallongo; Rita Gatti; Regina Tardanico; Andrea Scaloni; Chiara D'Ambrosio; Maria Luisa Carnevali; Piergiorgio Messa; Pietro Ravani; Giancarlo Barbano; Beatrice Bianco; Alice Bonanni; Francesco Scolari; Alberto Martini; Giovanni Candiano; Landino Allegri; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2014-05-01 Impact factor: 10.121
Authors: Basheer Khassawneh; Chengsong Zhu; Briana Barkes; Brian Vestal; Sarah Shrock; May Gillespie; Karin Pacheco; Kevin D Deane; Lisa A Maier; Quan-Zhen Li; Nabeel Hamzeh Journal: PLoS One Date: 2022-10-20 Impact factor: 3.752
Authors: Paolo Fagone; Karuppiah Muthumani; Katia Mangano; Gaetano Magro; Pier Luigi Meroni; Joseph J Kim; Niranjan Y Sardesai; David B Weiner; Ferdinando Nicoletti Journal: Immunology Date: 2014-08 Impact factor: 7.397